Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yes, at the request of NVAX all day today, Chat.
Has this not been trading all day?
Going with a recommend! Already have my calls purchased.
6000 share total now, either I miss or hit, by Wednesday I should know.
Did you see the subjects that developed the inflamed heart conditions were either already mrna vaxxed and the placebo to being statistical significant l definitely think it’s an overreaction and quite frankly manipulative in some ways.
I expect approval they have to with other countries including Canada are authorized to use
I thought the overall report was good. Bought the dip and we'll see how that turns out.
I thought the overall report was good. Bought the dip and we'll see how that turns out.
I added again on that ridiculous dip yesterday. This will recover next week.
B.Riley Financial Thinks Novavax’s Stock is Going to Recover
https://ih.advfn.com/stock-market/NASDAQ/novavax-NVAX/stock-news/88283845/b-riley-financial-thinks-novavax-s-stock-is-going
Placebo had basically the same lol
Here is a link to the FDA document, which was provided by Mouton29 on the Biotech Values board.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=169046552
It is depressing. The efficacy was good. The side-effects after the first dose wasn't an issue fine but what is troubling is the jump in grade 3 side effects after the second dose. I sold off 2/3 of my position based on that.
It may be that the FDA wasn't as aware or concerned about side-effect after the low incidence of myocarditis in mRNA vaccines than when they were approved. I looked up the incidence of myocarditis in mRNA vaccines but it is ~1 per 100,000, which is an order of magnitude lower than this reports says for NVAX.
128 million dollar buy at the bell, whether that was short covering or not. We will find out this week and next week.
Couldn't believe the opportunity after the 1st Q earnings report. NVAX makes a profit for the first time, confirms guidance, and gets hammered. Great opportunity to add shares.
I'm confident we'll get US approval and gain market share on the MRNA vaccine.
I watched this for 6 months and jumped in as I closed out a short Naz position. Couldn't believe the opportunity after the 1st Q earnings report. NVAX makes a profit for the first time, confirms guidance, and gets hammered. Great opportunity to add shares. I'm confident we'll get US approval and gain market share on the MRNA vaccine.
go Celts,
eastcoastguy
$20.00 EPS coming here after approval by end of next year.
I am sitting on 4000 shares. Just fasten your seatbelts and watch.
All time high by end of June.
All eyes on NVAX. All time high by end of June.
Can Novavax Rebuild Investor Confidence? Analyst Weighs In • TipRanks • 04/30/2022 12:51:27 AM
Novavax Shares Jump as FDA Plans Vaccine Review • Dow Jones News • 04/29/2022 03:17:00 PM
Novavax Inc (NVAX)
45.3 ? 1.03 (2.33%)
Volume: 7,743,242 @04/29/22 7:59:55 PM EDT
Bid Ask Day's Range
45.3 45.45 44.9 - 52.4796
NVAX Detailed Quote
Down to low 46... FDA delay and overall market may take it even lower...Was 4 bucks I think before covid so...YIKES!!!
When is Merck's production line for JnJ's dead end AVV vaccine going to come online?
Still cant figure out why gov't wanted to a retool protein-based manufacturing for AVV, instead of Novavax.
New Covid Variant XE Found In UK, More Transmissible Than Omicron: WHO
https://www.ndtv.com/world-news/new-covid-variant-xe-found-in-uk-more-transmissible-than-omicron-who-2858643
NVAX sure is a roller coaster ride. One day it will become a rocket ship, hopefully sooner rather than later.
Novavax Inc (NVAX)
73.49 ? -4.28 (-5.50%)
Volume: 2,953,331 @03/11/22 7:59:30 PM EST
Bid Ask Day's Range
73.02 73.5 72.56 - 80.481
NVAX Detailed Quote
NVAX needs to produce and deliver product. Approvals are no longer the issue.
Canada approves Novavaxs COVID-19 vaccine
10:27 AM ET 2/17/22 | Reuters
Canada approves Novavax's COVID-19 vaccine
Feb 17 (Reuters) - Canada's health regular said on Thursday it approved Novavax's COVID-19 vaccine for use in people aged 18 years and older.
The vaccine's safety and effectiveness in people younger than 18 years of age have not yet been established, Health Canada said in its release. (Reporting by Mrinalika Roy in Bengaluru; Editing by Devika Syamnath)
Novavax Statement on First Administration of its COVID-19 Vaccine in Australia
The first dose of Nuvaxovid™ COVID-19 Vaccine (recombinant, adjuvanted) was administered today in Australia during a press briefing by The Hon Greg Hunt MP, Federal Minister for Health and Aged Care. Nuvaxovid is the first protein-based COVID-19 vaccine to receive approval for provisional registration by the Therapeutic Goods Administration (TGA).
The TGA granted approval for provisional registration of Nuvaxovid for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 in individuals 18 years of age and older on January 19.
Novavax is proud to start delivering its vaccine to the people of Australia during a critical time as the pandemic shows no signs of retreat. Australia has played a pivotal role in Novavax' Phase 1 and Phase 2 clinical trials supporting the development of Nuvaxovid. Additionally, a booster trial for Nuvaxovid and a Phase 1/2 trial for a combination seasonal influenza and COVID-19 vaccine are currently underway in Australia.
Novavax and the Commonwealth of Australia have an advance purchase agreement for 51 million doses of Nuvaxovid, with the option for an additional 10 million doses (up to 61 million doses total). Plans are actively underway to begin the delivery process for Nuvaxovid doses across Australia.
2B doses were ordered. To start with. They simply need to be able to deliver.
https://www.nasdaq.com/market-activity/stocks/nvax/earnings
Going to be a fantastic year.
Novavax’s newest approvals position it as an mRNA ‘alternative’ that health officials say may convince vaccine skeptics
https://fortune.com/2022/02/04/novavax-vaccine-us-approval-uk-new-zealand-mrna-protein-alternative/amp/
Novavax Inc (NVAX)
89.65 ? 1.16 (1.31%)
Volume: 3,314,610 @02/04/22 7:59:50 PM EST
Bid Ask Day's Range
84.24 94.14 87.5 - 91.65
NVAX Detailed Quote
Novavax finally files...
NOVAVAX FDA FILING Jan 31 2022
Would be genuinely interested in Novavax’s outcomes for affinity maturation.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4456294/
Just want to know when and where I can get Nuvaxovid in my deltoid.
Come on FDA!
Not 80%. But, yeah, a lot. The high was 332 last February.
Who thought vaccine approvals would drop PPS 80%?
2 things against them right now… 1-the bio sector is getting the brakes shorted off of it and 2-they need to start shipping vaccines, there are a lot of hit pieces questioning there ability to produce…
Should be a no brainer for the fda since safety data is way superior and efficacy is comparable to existing shots.
Then again with the amount of crap coming from the fda and their overlords you never know.
Nothing suprises me at this point.
Edited....I wonder who could be responsible for those hit pieces??? Hmmmm...
Whats worse is that this shot could possibly get millions off the fence about getting the shot because its process is not new and a basic explanation given about how its made.
Guess we'll see soon enough.
Should be end of January, it is 30-days after the CMC package and it was submitted on December 31st…
Any word on them requeating eua from the fda?
Believe its already received it from the WHO and the EU.
Novavax vaccine is the most traditional covid vax yet since it uses the same process as the proven Hep b vax.
Those who are hesitant specifically because of safety concerns should be reassured by this.
Think who and ec has approved eua so whats up with the fda.
Followers
|
336
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
8516
|
Created
|
06/19/03
|
Type
|
Free
|
Moderators mick JoeForkeyBolo |
Novavax, Inc. is a clinical-stage biotechnology company committed to delivering novel products to prevent a broad range of infectious diseases.
Using innovative proprietary recombinant nanoparticle vaccine technology,
we produce vaccine candidates to efficiently and effectively respond to both known and emerging disease threats. More...
INVESTORS
Novavax is traded on the Nasdaq Stock Market under the symbol NVAX and is dedicated to developing novel vaccines to address infectious disease. More...
*DISCLAIMER *The Board Monitor and The Board Assistants herewith, are not licensed brokers and assume NO responsibility for the actions, investment decisions, and or messages posted on this forum.
• We do NOT recommend that anyone buy or sell any securities posted herewith. Any trade entered into risks the possibility of losing the funds invested.
• There are no guarantees when buying or selling any security.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |